{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/1b454f3a-002e-540e-82a0-3e5bcb0b5da9/1ae96b21-a327-4e5f-9373-a2954cfd2c2c?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg?height=200","description":"<p>Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety of dosages within the same subjects. In addition, past studies did not use pharmaceutically-defined dosages of LSD, which has made verifying the effects of a particular dose difficult. To address this gap, Matthias Liechti, professor in the department of clinical pharmacology and toxicology at the University of Basel in Switzerland, and his colleagues conducted a study.</p>","author_name":"Springer Nature"}